Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Kodiak Sciences Inc

(NASDAQ: KOD)
Add to Portfolio
-2.76 (-4.18%)
as of Jan 21, 2020

Last 63.30
Change -2.76 (-4.18%)
Open 65.92
Prev. Close 66.06
Today's Range
62.80
67.00
52wk Range
5.86
81.00
Volume 243,339
Avg Volume 471,600
Sector SIC-2836 Biological Products, (No Disgnostic Substanc

Perfomance Comparison

Name Today 3-Month 1-Year
KOD -4.18% +191.17% +644.71%
DJIA -0.52% +6.20% +18.17%
S&P 500 -0.27% +7.93% +24.34%

Key Statistics

Annual EPS -1.25
Dividend Yield 0.00%
P/E Ratio N/A
Market Capitalization, $K 2,448,060
Weighted Alpha +261.51
Standard Deviation -1.00
Profit Margin N/A
Beta 1.93

Growth Rates

YTD -12.02%
1-Year +677.18%

Opinion

Sell Hold Buy

Recent Headlines

Kodiak Sciences to Present at 38th Annual J.P. Morgan

PR Newswire via COMTEX - Wed Jan 08, 06:00AM EST
Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, announced today that management will present a company overview (full story)
JPM: 136.84 (-1.36), KOD: 63.30 (-2.76)

Uber, Lennar and Freeport-McMoRan rise

AP - Tue Dec 24, 02:12PM EST
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Tuesday:(full story)
LEN: 64.94 (+1.85), UBER: 37.60 (+2.47), KOD: 63.30 (-2.76), ROST: 117.80 (+0.12), FANG: 88.32 (-1.22), AXE: 99.13 (-0.04)

Kodiak Sciences Appoints Taiyin Yang, Ph.D., to Board

PR Newswire via COMTEX - Thu Dec 19, 04:01PM EST
Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced the appointment of Taiyin Yang, Ph.D., to its bo(full story)
GILD: 62.63 (-0.35), KOD: 63.30 (-2.76)

Kodiak Sciences Announces Closing of $317.4 Million

PR Newswire via COMTEX - Fri Dec 06, 04:15PM EST
Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced the closing of its previously announced underwri(full story)
JPM: 136.84 (-1.36), KOD: 63.30 (-2.76)

Kodiak Sciences Announces Pricing of $276.0 Million

PR Newswire via COMTEX - Tue Dec 03, 09:07PM EST
Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced the pricing of an underwritten public offering o(full story)
JPM: 136.84 (-1.36), KOD: 63.30 (-2.76)